Acadia Pharmaceuticals ACAD Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's deferred tax assets?
- Acadia Pharmaceuticals (ACAD) reported deferred tax assets of $249.62M in Q1 2026.
- What does deferred tax assets mean?
- Represents future tax benefits arising from temporary differences between the book value of assets/liabilities and their tax basis, or from carry-forward tax losses. These assets are realized when the firm generates sufficient taxable income to offset these differences. It serves as an indicator of future tax savings potential.